{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-001628","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.695498+00:00","generated_at":"2026-06-07T03:06:18.337447+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Twist Bioscience appoints Adam Laponis as CFO effective January 8, 2024","bullets":["Adam Laponis named CFO, effective Jan 8, 2024; succeeded James Thorburn.","Annual base salary of $450,000; signing bonus $195,000 with clawback if terminated for cause within one year.","Target annual incentive for 2024 at 55% of base salary; equity grant includes 50,000 RSUs (4-yr vest, 1-yr cliff) plus 70,000 shares under exec comp programs.","Laponis previously CFO at Eargo, VP at Tesla, VP/CFO at Cardinal Health, and held roles at Johnson & Johnson.","No family relationships or related-party transactions with Laponis; disclosure via prior 8-K for Thorburn’s departure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-001628","json":"https://secwatch.observer/filing/0001104659-24-001628.json","markdown":"https://secwatch.observer/filing/0001104659-24-001628.md","text":"https://secwatch.observer/filing/0001104659-24-001628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/0001104659-24-001628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/tm2333797d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:06:18.337447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49e1744a34","claim":"Adam Laponis was appointed as Chief Financial Officer at Twist Bioscience Corp.","evidence_excerpt":"On January 5, 2024, Twist Bioscience Corporation (the “Company”) announced the appointment of Adam Laponis as the Company’s Chief Financial Officer and principal financial officer, effective January 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/0001104659-24-001628-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"7265221a76","claim":"James Thorburn departed as Chief Financial Officer at Twist Bioscience Corp.","evidence_excerpt":"As previously reported by the Company in its Form 8-K filed on August 4, 2023 (the “Prior 8-K”), upon commencement of employment by Mr. Laponis, James Thorburn will no longer serve as the Company’s Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/0001104659-24-001628-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer serve"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}